Lilly's underappreciated TAM and pipeline
The bull case for Eli Lilly rests on an underappreciated total addressable market and a pipeline with potential in new disease indications beyond obesity.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.